• NMRD releases fiscal Q2-2021 results, provides business update
• Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board
• Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently released its fiscal Q2-2021 results and provided a business update (https://ibn.fm/TX286). Financial highlights from the announcement included $26.8M cash on hand, and receipt of an initial $513,000 as deposit payment from its UK licensee as partial payment for an order of 200,000 sensors and associated devices. Management expects to convert this and future invoiced payments to revenue once the Company begins delivering the final product to its licensee, scheduled to start during Q4-2021. NMRD is currently commercializing its sugarBEAT(R) and proBEAT(TM) non-invasive and flexible continuous glucose monitors that provide actionable insights from real-time glucose monitoring to help diabetic and pre-diabetic people better manage, reverse, and prevent the onset of diabetes. The Company recently welcomed Dr. Osama Hamdy, M.D., Ph.D., to its advisory board, who will take part and advise on diabetes and metabolic health studies using Nemaura’s glucose monitoring technology. Dr. Hamdy is a senior endocrinologist and medical director, Obesity Clinic Program at the Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School. Dr. Hamdy is a world-renowned thought leader in the field of obesity management in diabetes, medical nutrition and digital health. NMRD also announced the signing of a global commercial contract with MySugarWatch DuoPack Limited to provide continuous glucose monitors and sensors as Duo-Packs, to be sold with prescription-only medicines typically prescribed to people with Type 2 diabetes. “We continue to make progress in our commercializing efforts for sugarBEAT(R) in the UK and recognizing revenue from our licensee. We are also working closely with advisors to expand our footprint throughout the world to address the worldwide health crisis of diabetes using our skin-mounted needle-free CGM as an innovative solution for patients and consumers,” said Dr. Faz Chowdhury, CEO of Nemaura Medical. “Combined with our digital lifestyle management programs, we believe that our technology offering has the potential to be a key tool for the prevention and management of Type 2 diabetes. As we progress with our corporate, clinical, and regulatory milestones, we will provide future investor updates.” Founded in 2011, Nemaura initially developed a single platform technology to measure blood markers at the skin’s surface. The Company has since evolved with the creation of wearable technologies and digital health care solutions at the intersection of three rapidly growing markets: the global Type 2 diabetes market expected to reach $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable weight loss and wellness applications sector, estimated to reach $60 billion by 2023 (https://ibn.fm/0MG5U). With obesity and diabetes as the two major drivers fueling the chronic disease epidemic, NMRD is committed to preventing, managing, and reversing these conditions by offering non-invasive, affordable, and flexible glucose monitoring solutions. For more information, visit the company websites at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Report notes significant and swift advancements in company R&D pipeline and overall business
• Preliminary data indicates CYB003 may provide significant treatment benefits that address limitations of oral psilocybin
• CYBN programs and new psychedelic chemical entities have potential to transform treatment landscape for various psychiatric and neurological conditions

Q2 2021 has been a transformative quarter for Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM). The company released its financial and operational report for the period recently, with notable company milestones and achievements highlighted (https://ibn.fm/ucAed). “The first half of the year has been a transformative period for Cybin that included significant and swift advancements in our research and development pipeline and overall business,” said Cybin CEO Doug Drysdale. “Through CYB003, we believe that we have identified a potentially safer treatment option for patients with depression and addiction disorders that we expect to have strong intellectual property protection and a positive pharmacokinetic profile for patients, providers and payers. We plan to move through the ongoing, remaining preclinical studies quickly and submit an investigational new drug application and clinical trial application in the second quarter of 2022¹, in the U.S. and the U.K. respectively.” Cybin’s novel deuterated psilocybin analog, CYB003, was the focus of a preclinical study designed to explore and study the substance for potential treatment of major depressive disorder and alcohol use disorder. The company recently reported preliminary data indicating that CYB003 may provide significant treatment benefits that successfully address the challenges and limitations of oral psilocybin; those benefits include improved safety through less patient variability, reduced clinic times through faster onset of action and shorter duration of effect, and lower dosing through improved brain penetration. The company noted that the study also shows the treatment may produce fewer side effects. All of this points to an overall improved patient experience. In its report, Cybin noted that it plans to complete the ongoing CYB003 preclinical studies in the first quarter of 2022. By Q2 2022, the company anticipates submitting an investigational new drug application to the U.S. Food and Drug Administration and a clinical trial application with the U.K. Medicines and Healthcare Products Regulatory Agency. Other notable company achievements during the quarter include the U.S. Drug Enforcement Agency’s approval of a Schedule I manufacturing license for Cybin’s research lab, which is located in Boston. This license will enable CYBN to expand its internal research and development capabilities. The company also received FDA approval for its IND application to proceed with a feasibility study using Kernel Flow quantitative neuroimaging technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. In addition, Cybin launched a first-of-its-kind psychedelic facilitator training program, based on EMBARK, a groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine (https://ibn.fm/zWTkO). “We continue to evolve our value-driving, patient-centered approach to potential treatments for mental health and addiction through our commitment to advancing programs such as EMBARK, that aims to facilitate psilocybin-assisted psychotherapy for frontline workers impacted by the COVID-19 pandemic, as well as targeted research using the Kernel Flow neuroimaging technology that we expect will allow us to quantitively understand the psychedelic experience in the brain as it is happening. We believe these programs combined with our proprietary psychedelic new chemical entities have the potential to transform the treatment landscape for various psychiatric and neurological conditions.” Cybin is focused on progressing psychedelic therapeutics, making it an ideal advocate and sponsor of the EMBARK approach. A leading biotechnology company, Cybin is working to progress psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• The global cannabis market was valued at $22.10 billion and is expected to grow at a CAGR of 13.9% by 2026. The growing trend was reflected by Green Wednesday sales
• MCOA has expanded its interests into Latin America and has strategic partnerships in place, as well as wholly-owned subsidiaries in its portfolio
• Leadership team has set high standards for the company and plans to leverage the strategic partnerships it has accumulated as a means of facilitating growth for the company within the industry

The cannabis industry just celebrated its second-largest holiday of the year – Green Wednesday, the industry’s very own “Black Friday.” According to software company Akerna’s figures, the sale of legal cannabis products during the four-day holiday (November 24-27) is likely to have topped $251 million. The forecast also estimated that sales would equate to a 78% spike from normal daily sales on Green Wednesday, resulting in $90 million worth of legal products being sold (https://ibn.fm/gcGjw). The Green Wednesday sales increase reflects a growing trend of the industry as a whole. The global cannabis market was valued at $22.10 billion in 2020 and is expected to grow at a CAGR of 13.9% during the 2021 to 2026 forecast period. Much like other industries around the world, the marijuana market was significantly impacted by the COVID-19 pandemic. The limitations placed on brick-and-mortar establishments presented many setbacks and forced store owners to seek other methods to sell products, like on social media platforms and e-commerce sites (https://ibn.fm/oWxDU). In the interest of global expansion, Marijuana Company of America (OTC: MCOA) has taken steps to extend the company’s reach into new regions, including Latin America, and to leverage current strategic partnerships with several companies and its wholly-owned subsidiaries to facilitate growth in an industry that continues to expand despite recent setbacks. Companies that MCOA has partnered with include:

• Cannabis Global Inc. (OTC: CBGL) – CBGL is an up-and-comer in the cannabis industry. It has a growing product and intellectual property portfolio. The company is currently marketing and producing an innovative cannabis storage, transport, and tracking solution called Comply Bag(TM) and is the developer and marketer of the Hemp You Can Feel(TM) brand.
• Eco Innovation Group Inc. (OTC: ECOX) – MCOA’s investment supports ECOX’s cutting-edge and innovative extraction technology. The technology utilizes a proprietary formulation that extracts bioactive compounds from cannabidiol (“CBD”) which is combined with plant-based materials creating a fluid and cost-effective outcome.
• Natural Plant Extract – NPE is a direct investment interest that operates a licensed cannabis manufacturing and distribution business in Lynwood, California. NPE’s Type 7 California manufacturing and distribution license allows for product distribution anywhere in the State of California.

MCOA’s wholly-owned subsidiaries include:

• hempsmart(TM) – A CBD company focused on creating and promoting the most effective and best tasting products with the highest quality on the market. During 2021, the company rebranded and took a fresh take on its packaging – leveraging a social media campaign to entice customers to purchase its premier products, including Smart Drops, Neuro Smart, and Smart Cream.
• cDistro – cDistro is the company’s distribution arm for CBD brands, along with smoke and vape shop-related products, wholesalers, c-stores, specialty retailers, and consumers across North America. cDistro has been selected as one of the first to distribute Marley One.
• VBF Brands Inc. – MCOA’s acquisition of VBF will offer exponential growth potential with other nearby properties, which the company will have the opportunity to work with as a result of the acquisition.

MCOA’s leadership team sets high standards of integrity and professionalism for the company’s employees, officers, and directors. As the company expands into new regions around the world, it intends to utilize its resources and strategic partners’ success to continue diversifying is product and services and provide consistent value to its shareholders while securing a leading position on the legal cannabis and industrial hemp markets. For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com. NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Several factors could contribute to 12.71% projected CAGR in nootropics global market
• Rise in demand for cognitive enhancers (smart drugs that enhance memory and focus) is expected to foster growth
• The Happy Co. has become the category creator for Happy Coffee and a recognized leader in natural nootropics

A recent Verified Market Research report noted that the global market for nootropics reached $2.42 billion in 2020 and is projected to top $6.29 million by 2028, growing at a CAGR of 12.71% from 2021 to 2028 (https://ibn.fm/MdSBu). Sharing Services Global (OTCQB: SHRG) subsidiary The Happy Co., a direct-sales opportunity that offers functional beverages, capsules, patches and creams featuring nootropics, could see significant benefit from this growth. “The rise in demand for cognitive enhancers or smart drugs among the global population in order to enhance memory and stay focused is expected to foster the growth of the global nootropics market,” the report stated. “The rising focus of manufacturers to develop natural or organic ingredients-based supplements in order to target customers is likely to drive the market growth.” The report went on to note that increase in demand from the sports industry for mind-boosting drugs will also impact the market. “The popularity and acceptance of nootropics as an enhancement or medication is attracting new market players in this market, which will lead to the growth of the nootropics market,” the report continued. “Increasing awareness regarding the importance of psychological wellness and accessibility of these medications at various online and offline platforms are among the key components impelling the development of the nootropics market.” In addition, nootropics drugs, which work as antidepressants, energy boosters, and anxiety resistance, could see increased R&D efforts, the report observed. “Due to their large benefits, they are preferred by individuals, and hence this is expected to encourage R&D in the nootropics market. Newer technological innovations in the nootropics market will lead to the growth of this industry.” One of the fastest-growing companies in the social-marketing and direct-selling industries, SHRG subsidiary The Happy Co. has become the category creator for Happy Coffee and a recognized leader in natural nootropics. The company offers a wide array of nootropic products, from oils and capsules to patches and powders. Each offering has been carefully formulated to provide the knowledge that comes from experience, which the Happy Co. is confident will prove the value and worth of its products to eager consumers everywhere. Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• NUGS “wasting no time” in deploying assets to launch one of California’s top vertical cannabis models
• Company plans to deploy another new license for establishment of indoor cultivation facility
• Four licenses provide regulatory backing for a series of major next steps critical to NUGS’ strategy

An emerging leader in the U.S. cannabis marketplace, Cannabis Strategic Ventures (OTC: NUGS) is taking key steps forward in its strategic plan to implement a farm-to-sale model (https://ibn.fm/r7DFR). The company is beginning to deploy its newly acquired licenses, including the opening of its first Los-Angeles-based, customer-facing MDRN (Modern) Tree cannabis dispensary. “After securing key licensing, we are wasting no time in deploying those assets to launch one of California’s top vertical cannabis models,” stated NUGS CEO Simon Yu. “MDRN Tree will be our factory retail store — our direct interface with our end-market community — where we plan on showcasing the cannabis flower produced at our NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability, and I look forward to providing further updates as we make strides in this direction.” After the launch of MDRN Tree, NUGS plans to deploy another of its new licenses for the establishment of an indoor cultivation facility with the capability of up to 1,200 grow lights. Based on that, the facility could produce anywhere from two to three pounds of premium exotic cannabis flower per light per harvest, with an estimated 5.75 harvests per year. The company projects “an upside potential for total production capacity of over 15,000 lbs. of premium exotic cannabis flower per year.” These milestone moves are the result of an agreement the company entered into last year where the company received a cash investment of up to $8 million in funding and the assignment of four cannabis licenses: retail, cultivation, distribution and manufacturing. The license transfer was finalized in September of this year, but NUGS has only officially taken over the accounting and operations of existing retail locations. The company is in the process of identifying the next steps to take over the remaining licenses following by cultivation operations. The global pandemic slowed progress on NUGS’ strategic development of its plans, but the company is now moving forward. “We are thrilled to finally get past these delays,” said Yu (https://ibn.fm/sZr5s). “These four licenses provide the regulatory backing for a series of major next steps critical to realizing our vision of becoming a top-tier, farm-to-door vertically integrated premium cannabis company with dominant positioning in the thriving California cannabis marketplace.” According to Yu, the company is moving quickly to deploying these new assets to launch one of California’s top vertical cannabis models. “MDRN Tree will be our factory retail store – our direct interface with our end-market community – where we plan on showcasing the cannabis flower produced at our NUGS Farm North cultivation site,” said Yu. “This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability, and I look forward to providing further updates as we make strides in this direction.” Cannabis Strategic Ventures Inc. is a publicly traded cannabis cultivators in the United States. The company focuses on medical and legal recreational cannabis sector. The company provides temporary, permanent and long-term staffing solutions, employment and human resources consulting to the legal cannabis sector. In addition, the company’s wholly owned subsidiary, NUGS Farm North, is a legal state-licensed cannabis cultivator in the state of California with more than six acres of greenhouse. For more information, visit the company’s website at www.CannabisStrategic.com. NOTE TO INVESTORS: The latest news and updates relating to NUGS are available in the company’s newsroom at http://ibn.fm/NUGS

At the recent 2021 OPSTech forum produced by The Monitoring Association (“TMA”), Microsoft (NASDAQ: MSFT) drilled home the premise that technology stakeholders need to embrace and understand the potential of artificial intelligence (“AI”). The company’s Azure platform is a framework for developing AI solutions for enterprises. Enterprises want to modernize their business processes quickly, and the Azure Artificial Intelligence Platform enables users to deliver breakthrough experiences via the use of industry-leading Vision AI models. “Today’s leading-edge technologies, such as AI, give security integrators and monitoring services companies the ability to deliver new, higher levels of comfort, convenience, and security,” stated TMA President Morgan Hertel. “For our industry to compete successfully, service providers need to gain a strong understanding of AI and other technologies that are quickly emerging and gaining consumer interest.” See the Latest Developments within the AI Space and Other Emerging Market Sectors To view the live presentations to be delivered at the upcoming virtual Sidoti Conference, register at https://www.sidoti.com/events About Sidoti For over two decades, Sidoti has been a premier provider of independent securities research. Our approach affords companies and institutional clients a combination of high-quality research and broad access to corporate management teams. We serve 500+ institutional clients in North America. Sidoti promotes meaningful interaction between issuers and investors through conferences and the hundreds of non-deal roadshows we host each year. For more information on Sidoti, visit https://www.sidoti.com About IBN (InvestorBrandNetwork) IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal. For more information on IBN, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Date: December 2-3, 2021 Venue: Virtual Sustain SoCal and ROTH remain committed to their members, clients, and employees’ well-being and safety. This year’s event will feature virtual sector focus panels with ROTH Research Analysts and Bankers, as well as virtual 1-on-1 / small group discussions. Investors from venture capital, private equity, family offices, endowments, foundations, and angels will be able to engage with C-level executives from established private sustainability companies in the AgTech, energy, environmental, mobility, transportation, and water verticals in this format. Key aspects of this event:

• Sustainability Private Capital is a virtual event that takes place over two days
• There is no cost to attend any of the sessions or gatherings
• The public can register for the panel sessions
• A separate registration is required for each panel session
• Sector-focused 1-on-1 / Small Group meetings (by invitation only) are 25 minutes Meetings are held with a 5-minute break in between

Who’s Organizing This Event? In Southern California, Sustain SoCal, a non-profit organization, promotes sustainability and economic growth via innovation, collaboration, and education. The organization has a ten-year track record of identifying and executing practical, real-world solutions to the problems that growth, change, and inefficiency bring. It organizes conferences, workshops, and networking events that lead to projects that improve the economic prosperity and sustainability of our region. They are now reaching out to the most significant private sustainability companies and investors across the United States. Sustain SoCal and Roth invite you to join them in bringing sustainability and private money together. Why Should You Attend It? With a multitude of attending companies, numerous pavilions, events, attractions, and experiences, Sustainability Private Capital Event aims to inspire and initiate change and create a better future with a focus on sustainability, opportunity, and mobility. Students and instructors, on the other hand, will find plenty to consume and learn about, from specially created educational activities to excursions. Meanwhile, investors and businesses can network by attending international forums and conferences. How To Register? If you are interested in attending, please visit to submit a registration request or www.roth.com/sustainvirtual contact your ROTH and/or Sustain SoCal representative. This is an invite-only event & registration, which is complimentary, and is subject to approval. For more information, please visit https://ibn.fm/0Bzen

• Playgon CEO Darcy Krogh recently featured on IBN’s Bell2Bell podcast
• PLGNF develops and licenses digital content for global iGaming market
• Company surpassed $60 million in player betting turnover in October, up from $1.6 million in September with at least 100% growth across all key indicators
• PLGNF’s proprietary technology enables seamless integration at operator level, allows user access without sharing sensitive data or requiring app store download

Darcy Krogh, CEO of Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), was recently featured on Bell2Bell, a podcast produced by the Investor Brand Network (“IBN”) that delivers critical updates and exclusive interviews with executives operating in hyper-growth industries (https://ibn.fm/hfJpb). PLGNF, a SaaS technology company that focuses on developing and licensing digital content for the global iGaming market, recently surpassed $60 million in player betting turnover in October, up from $1.6 million for the entire month of September with at least 100% growth across all key indicators (https://ibn.fm/CX8YI). Krogh revealed details about the company’s successful growth strategy during the episode, along with insights into the rapidly expanding iGaming sector. “Playgon is a software development company. We build digital content for the growing and exciting online gaming space,” Krogh said. “We’re 80 strong with employees, including 20 engineers, with our core product being live dealer table games. We have 60 dealers in our studio in Las Vegas who deliver the content to our customers. We’re a mobile-focused development company, and we license our product out of Malta. We are a public company, and we are growing quite quickly.” PLGNF’s proprietary software provides a multi-tenant gateway that enables online operators to offer users popular games such as, Live Dealer Casino, E-Table Games and Daily Fantasy Sports. With high-definition live streaming dealers and state-of-the-art augmented reality technology, PLGNF delivers an authentic casino experience streamed live from Las Vegas through a seamless integration at the operator level and allows user access without sharing sensitive data or requiring an app store download. “Our company has a B2B model, basically a typical SaaS model where we share in revenues with our operator customers under a licensing agreement,” said Krogh. “We plug into existing legacy systems that they run digitally, and create a highway into our studio, which we have in Vegas. We offer the Live Dealer content from North America. The beautiful thing about this model is that we have no player acquisition cost, and it’s a global strategy.” According to a recent report by Research and Markets, the online gaming industry is expected to grow at a CAGR of 11.94% between 2021-2026 (https://ibn.fm/dmk2N), and Grandview Research expects the market to reach $127.3 billion by 2027 (https://ibn.fm/VLFJG). “I first got into the business late in the ‘90s, so I’ve two decades in this industry,” said Krogh. “I’ve seen it grow up from mom-and-pop operations in the Caribbean to the business that it’s grown into today where, by-and-large, it’s run and owned by a lot of the big gaming brands.” PLGNF provides turn-key solutions for online casinos, sportsbook operators, land-based operators, media groups, and big database companies. The company’s management team leverages three decades of iGaming experience, with multiple successful exits. With a portfolio of IP-protected assets and high barriers to entry, the company is positioned favorably within the rapidly growing iGaming industry. To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com. For more information, visit the company’s website at www.Playgon.com. NOTE TO INVESTORS: The latest news and updates relating to PLGNF are available in the company’s newsroom at https://ibn.fm/PLGNF

• Mydecine’s recent Q3 update includes the company’s five-year research agreement with Johns Hopkins University School of Medicine, which will cover clinical research related to the therapeutic use of psychedelics
• Mydecine has also filed for various patents on proprietary compounds within the company’s IP portfolio
• In addition, an updated version of the company’s virtual health platform, Mindleap 2.0, was released in Q3, enhancing user experience, infrastructure improvement, and expansion of overall content

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA), a company that focuses on bio- and digital technology that aims to transform the treatment of mental health and addiction disorders, has released financials and a business update for the third quarter ending September 30, 2021 (https://ibn.fm/RKapA). The highlight of this quarter was the five-year research agreement Mydecine Innovations entered with Johns Hopkins University School of Medicine, one of the most experienced university departments in conducting clinical research related to the therapeutic use of psychedelics, according to CEO Joshua Bartch. The five-year master collaboration research agreement with Johns Hopkins University gives the company’s medical and scientific research teams the resources needed to explore things like different indications, enhanced delivery, improved dosing, shorter half-life or other improvements needed to advance our understanding of these medicines in medical practice. In collaboration with JHU, the company is rapidly advancing one of its lead candidates, MYCO-001, through clinical trials with an upcoming seamless Phase 2/3 smoking cessation clinical trial and a JHU multi-site NIDA grant-funded smoking cessation study, which will use MYCO-001. “This marks the first time in over 50 years that the U.S government has funded a study of a psychedelic compound for therapeutics,” Bartch explained. “As we prepare for the launch of these trials, we expect to meet with the FDA for Pre-Investigational New Drug Application (Pre-IND) meetings in early 2022, another step closer to bringing to market more effective treatments for today’s unmet needs in mental health and addiction.” The research agreement is a good indication of the company’s commitment to advancing psychedelic medicine as a whole, since, unlike some competitors, they are not just focusing on psilocybin or MDMA. “The long-term potential of this research agreement is captivating for us here at Mydecine,” Chief Scientific Officer and Co-Founder of Mydecine, Rob Roscow, stated. “It demonstrates our commitment to advancing psychedelic medicine by exploring multiple molecules and medicines for a variety of indications.” IP Portfolio During the third quarter, Mydecine also filed three patent applications and successfully synthesized a novel psilocin analogue with improved pharmaceutical properties. The patents include a final patent for MYCO-003, developed for enhanced treatment of anxiety and PTSD, with the US Patent and Trademark Office and the World Intellectual Property Organization. The other two patents refer to an MDMA-like compound and one for technology using nanoemulsion to enhance, stabilize, and make repeatable properties of ingredients from traditional medicine. Technology and Corporate During the same reporting period, Mydecine successfully launched Mindleap 2.0, an updated version of the company’s proprietary virtual health platform – providing better user experience, infrastructure, and overall content expansion. The company continues to work on developing an AI-driven drug discovery program that screens billions of new drug candidates and filters them for the ability to modulate an activity of psychedelic-related targets. In terms of financials, the company reported total cash and cash equivalent of $1.6 million for the quarter’s end. Net losses attributed to common stockholders totaled $4.5 million, equivalent to a per-share loss of $0.02, down from the $17.4 million loss reported during Q3 2020 Additionally, Mydecine has completed its spin-out transaction of ALT House Cannabis Inc., which now holds the company’s U.S. cannabis assets. This allows the Mydecine team to shift focus on the company’s core drug development processes. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

Date: December 15–17, 2021 Venue: Moscone Center, San Francisco, California NCIA’s 7th Annual Cannabis Business Summit & Expo will be held in the Moscone Center in San Francisco, California, on December 15–17, 2021. Presented by the National Cannabis Industry Association (“NCIA”), the only national trade association advancing the interests of the responsible cannabis industry, #CannaBizSummit is the industry’s most influential national B2B trade exhibition and the only event that brings together a lineup of unique education, exhibitors, and experiences all under one roof. Joining a prestigious lineup of more than 125 industry presenters in over 80 educational sessions, the event’s keynote speakers include Troy Datcher, CEO of The Parent Company, as well as elite athletes Marvin Washington, Rachael Rapinoe, Calvin Johnson, Jr., and Anna Symonds. On a 12,000 square foot show floor, #CannaBizSummit will also feature hundreds of exhibitors from the full cannabis ecosystem. Highlights include:

• Learn secrets of the trade to help you get your cannabis business future-ready — even in the face of economic and environmental change.
• Gain knowledge that is driving the next generation of innovation.
• Watch live recordings and join your favorite podcasts on the Live Podcast Stage.
• Shop, watch demos, and compare the newest technology, goods, and services, side by side on the Expo floor.
• Attend networking opportunities to reconnect with colleagues and build meaningful new business connections.
• Get hands-on with cannabis goods at the new BLOOM: A Brands Experience. See, touch, and smell products from across the country in flower, pre-rolls, vapor, oil, edibles, and more, for the first time ever on the #CannaBizSummit Expo floor.

The Location The venue for this year’s #CannaBizSummit was chosen for its historical significance in the cannabis industry. San Francisco is not only the entryway to the Emerald Triangle, the country’s largest cannabis-growing region, but it is also the epicenter of the reform movement. NCIA’s 7th Annual Cannabis Business Summit & Expo takes place as the city marks the 30th anniversary of the 1991 “Proposition P” ballot initiative that legalized medical cannabis in San Francisco, and the 25th anniversary of California’s landmark Proposition 215, which extended medical legalization statewide. You May Be Able to Attend for Free! With unique content presented by the best and brightest minds in the industry, unmatched networking opportunities, and hundreds of exhibitors, this is an experience you won’t want to miss. Plus, licensed retailers, distributors, infused product manufacturers, and cultivators with a valid state license can attend on a complimentary basis. For more information, please visit https://ibn.fm/ZUMXO.